Select B-ALL-enriched, promoter-distal DASs predicted to be AP-1 bound by TF footprinting within B-ALL patient samples but not Pro-B cells were targeted for CRISPR-Cas9-mediated genomic deletion in B-ALL cell lines (Figure S3). This evidence concerns the gene FOS and acute lymphoblastic leukemia.